Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.63 |
| ▸ | CCR5 | P51681 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372041 | 0.92 | CCR2 (0.63) | CCR2KCNH2CCR5MAPT | |
| SCHEMBL2492309 | 0.92 | CCR2 (0.63) | CCR2KCNH2CCR5MAPT | |
| SCHEMBL13829072 | 0.91 | CCR2 (0.62) | CCR2KCNH2CCR5MAPT | |
| SCHEMBL1943067 | 0.91 | CCR2 (0.76) | CCR2KCNH2CCR5 | |
| SCHEMBL1942782 | 0.91 | CCR2 (0.76) | CCR2KCNH2CCR5 | |
| SCHEMBL2489338 | 0.88 | CCR2 (0.58) | CCR2KCNH2CCR5MAPT | |
| SCHEMBL13829019 | 0.87 | CCR2 (0.60) | CCR2KCNH2CCR5MAPT | |
| SCHEMBL2487141 | 0.87 | CCR2 (0.64) | CCR2KCNH2CCR5 | |
| SCHEMBL13303701 | 0.86 | CCR2 (0.59) | CCR2KCNH2CCR5MAPT | |
| SCHEMBL2488378 | 0.86 | CCR2 (0.58) | CCR2KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727913-A1 | (4-Tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-N-carboxamide derivatives | Astrazeneca AB (SE) | 2014-05-07 | — | — | EP | disclosed |
| EP-2727913-A1 | (4-Tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-N-carboxamide derivatives | Astrazeneca AB (SE) | 2014-05-07 | — | — | EP | disclosed |
| US-20130289043-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289043-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289043-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-31 | — | — | US | disclosed |
| US-20120289513-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289513-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289513-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| EP-2379519-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010071567-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071567-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152197-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152197-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152197-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289043-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | CCR2, CCR5, CNR2 | CCR2 1/4885KCNH2 1324/4885CCR5 2/4885 |
| US-20100152197-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | CCR2, CCR5, CNR2 | CCR2 1/4885KCNH2 1324/4885CCR5 2/4885 |
| US-20120289513-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | CCR2, CCR5, CNR2 | CCR2 1/4885KCNH2 1324/4885CCR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.